Skip to Content

Axumin FDA Approval History

FDA Approved: Yes (First approved May 27, 2016)
Brand name: Axumin
Generic name: fluciclovine F 18
Dosage form: Injection
Company: Blue Earth Diagnostics, Ltd.
Treatment for: Diagnosis and Investigation

Axumin (fluciclovine F 18) a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected recurrent prostate cancer.

Development Timeline for Axumin

DateArticle
May 27, 2016Approval FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.